The purpose of this study was to evaluate the feasibility of living donor liver transplantation for treatment of patients with hepatocellular carcinoma and segmental portal vein tumor thrombus (PVTT) below the second-order branch. Between January 2005 and December 2015, we retrospectively analyzed 242 patients in a control group (n 5 184), a microvascular invasion (MVI) group (n 5 24), and a PVTT group (n 5 34). To assess the risks associated with PVTT, we evaluated recurrence, the disease-free survival (DFS) rate, the overall survival (OS) rate, and various other factors based on the characteristics of patients and tumors. Of the 242 patients, 5-year DFS and OS rates were 79.5% and 70.7%. A total of 34 (14.0%) patients had PVTT, of whom 7 had lobar PVTT in first-order branches. The control, MVI, and PVTT groups significantly differed in terms of tumor morphology (maximal and total diameters) and biology (alpha-fetoprotein [AFP] and protein induced by vitamin K absence or antagonist II). The control, MVI, and PVTT groups significantly differed in terms of the recurrence, DFS, and OS rates. Especially, lobar PVTT reduced the 5-year DFS and OS rates to dismal and 14.3%, respectively, but segmental PVTT was associated with favorable 5-year DFS and OS rates (63.9% and 50.3%, respectively). We found no statistically significant difference in the DFS and OS rates of patients with MVI alone and segmental PVTT alone. In patients in the segmental PVTT group with AFP levels of <100 ng/mL, the 5-year DFS and OS rates were 90.9% and 71.3%, respectively. In conclusion, a tumor thrombus in a lobar portal vein remains a contraindication to liver transplantation. However, a segmental PVTT is acceptable, especially when the AFP level is <100 ng/mL.
Hepatocellular carcinoma (HCC) is a major health care issue; the condition causes more than 1 million deaths annually worldwide.
(1) Most patients with HCC have concomitant liver cirrhosis, caused mainly by hepatitis B virus (HBV) and hepatitis C virus (HCV). Liver transplantation (LT), unlike hepatic resection, has the advantage of treating not only the tumor, but also the underlying liver cirrhosis.
LT was established as a suitable treatment for HCC when Mazzaferro et al. developed the Milan criteria in 1996. (2) Thereafter, LT has achieved optimal results in well-selected candidates; most international transplantation communities have adopted the Milan criteria for treatment of HCC. However, approximately 70% of patients with HCC are diagnosed with advanced-stage disease. (3) Even among patients who initially meet the Milan criteria, 20% are removed from waiting lists because HCC progression leads to violation of these criteria. (4) (5) (6) The current Milan criteria are too strict; most centers agree that they should be expanded. Therefore, living donor liver transplantation (LDLT) is emerging as an additional therapeutic option. Prior to LDLT, the donor and recipient can be matched; the decision to operate is based on the risk to the donor Abbreviations: AFP, alpha-fetoprotein; CT, computed tomography; DDLT, deceased donor liver transplantation; DFS, disease-free survival; E-S, Edmondson-Steiner; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LDLT, living donor liver transplantation; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; MMF, mycophenolate mofetil; MRI, magnetic resonance imaging; MVI, microvascular invasion; OS, overall survival; PET, positron emission tomography; PIVKA-II, protein induced by vitamin K absence or antagonist II; PV, portal vein; PVTT, portal vein tumor thrombus. and the expected benefit to the recipient. Patient selection criteria for LDLT are generally wider than those for deceased donor liver transplantation (DDLT).
It is widely accepted that LT should not be performed when a portal vein tumor thrombus (PVTT) is present, due to the poor prognosis in such patients. However, expanded selection criteria are acceptable for LDLT. LT is permitted in patients with branched PVTT, depending on the details of the situation. However, the outcomes of LT in those with branched PVTT remain unclear. The purpose of the present study was to evaluate the feasibility of LDLT as treatment for HCC in patients with branched PVTT; we explored whether LDLT compromised patient survival.
Patients and Methods
Between January 2005 and December 2015, 253 adult patients underwent LDLT to treat HCC at our institution. After excluding 4 postoperative mortalities, 5 cases lost to follow-up, and 2 cases of HCC with cholangiocarcinoma, we retrospectively analyzed 242 patients. We defined postoperative mortality as expiration within 1 month of transplantation. All patients were adults, and right lobes were used for transplantation. The median follow-up duration was 52 months (10-141 months). The institutional review board of our center approved the study design.
All patients with HCC who were scheduled for transplantation were evaluated preoperatively by computed tomography (CT) of the abdomen and chest, enhanced magnetic resonance imaging (MRI), positron emission tomography (PET)-CT, bone scintigraphy, gastrofiberscopy, and colonoscopy. Alphafetoprotein (AFP) levels and those of protein induced by vitamin K absence or antagonist II (PIVKA-II) were evaluated; these levels are tumor markers. Absolute contraindications for LT in patients with HCC included tumor thrombus in the main portal vein (PV), regional lymph node metastasis, and distant metastasis. In other patients with advanced HCC, such as those with branched PVTT, we proceeded only with the consent of the living donor and recipient after a full discussion about the possibility of recurrence.
LDLT was performed using a standard technique; we employed modified right lobe with middle hepatic vein reconstruction. When ascites was present, ascites was aspired and evaluated cytologically prior to operation. When lymph node enlargement was evident or metastasis was suspected, intraoperative biopsy was performed. The operation continued only when the biopsy results were negative. Immunosuppressive treatment included a regimen featuring a calcineurin inhibitor (cyclosporine or tacrolimus) as a component of a double-or triple-drug cocktail (the other 2 drugs were prednisone and mycophenolate mofetil [MMF] ). An interleukin 2 receptor blocker was administered on the day of the operation and the fourth postoperative day. Steroids were withdrawn 1 month after surgery, and MMF was withdrawn 6 months after surgery. Only a low-dose calcineurin inhibitor was given after this period. The immunosuppressive protocol did not differ from that used to treat benign diseases. When recurrence was detected during follow-up, the immunosuppressive agent was changed to everolimus or a low trough level of the immunosuppressant was maintained.
To allow early detection of recurrence, AFP and PIVKA-II levels were checked monthly during the first year and bimonthly thereafter. Abdominal CT, chest CT, and bone scintigraphy were performed routinely every 6 months during the first 2 years, and annually thereafter. MRI and/or PET-CT were performed when tumor recurrence was suspected.
We retrospectively reviewed the demographics of all LDLT patients in terms of HCC status, tumor diameter, and number of tumors, based on pathology reports. PVTT was diagnosed preoperatively when intrathrombus vascularity was evident in the arterial phases of imaging studies (CT or MRI) just before LT. And finally, PVTT was pathologically confirmed in the explant liver. A PVTT below the second-order branch was defined as segmental; a PVTT in the first-order branch was defined as lobar. To assess the risk of PVTT, we divided patients into a control group (no microvascular invasion [MVI] or PVTT); an MVI group (MVI only; no PVTT); and a PVTT group. We evaluated recurrence, the disease-free survival (DFS) rate, overall survival (OS), and various other patient and tumor characteristics.
STATISTICAL ANALYSIS
Numerical data are presented as means with standard deviations. Continuous variables (means, standard deviations, medians, and ranges) were analyzed using the independent t test or the chi-square test, and proportions were compared using Pearson's chi-squared and Fisher's exact tests. DFS and OS rates were estimated using the Kaplan-Meier method, and survival curves were compared with the aid of the log-rank test. All statistical analyses were performed using SPSS software, version 19.0 (IBM SPSS Statistics, Chicago, IL). P values < 0.05 were considered to indicate statistical significance.
Results
We followed the 242 patients who underwent LDLT to treat HCC until November 2016. Their mean age was 52.99 6 7.13 years (range, 33-72 years), and 201 (83.1%) were male. The underlying liver disease was usually caused by HBV infection (82.6%), followed by HCV infection (7%). The average Child-Pugh score was 7.53 6 2.48, and the average Model for EndStage Liver Disease (MELD) score was 11.41 6 7.20. A total of 190 (78.5%) patients had undergone preoperative treatment. The mean AFP and PIVKA-II levels were 262.10 6 1063.24 ng/mL and 385.48 6 2044.15 mAU/mL, respectively. The mean maximal and total tumor diameters were 3.14 6 2.60 cm and 4.68 6 3.49 cm, respectively. The mean tumor number was 2.59 6 2.22. High Edmondson-Steiner (E-S) grades (3-4) were evident in 62 (30.2%) patients. MVI was apparent in 52 (21.5%) patients, and PVTT was detected in 34 (14%) patients. Of these 34 patients, segmental PVTT was noted in 27 (79.4%) and lobar PVTT in 7 (20.6%). All lobar PVTTs were diagnosed by preoperative imaging, but among segmental PVTT patients, 16 (59.3%) patients were diagnosed preoperatively by abdominal CT and MRI, and the rest were confirmed in explant liver after surgery. Recurrence developed in 44 (18.2%) of the 242 patients during the follow-up period. The first recurrence site was the liver in 13 (29.5%) patients and an extrahepatic site in 31 (70.5%) patients. A total of 26 (59.1%) recurrences occurred within the first year and 33 (75.0%) occurred within the second year.
We compared various relevant parameters according to recurrence status (yes or no). The AFP level (P 5 0.03), the maximal (P 5 0.01) and total (P 5 0.01) tumor diameters, the tumor number (P 5 0.048), MVI status (P < 0.001), E-S grade (P 5 0.002), and PVTT status (P < 0.001) all differed significantly between the nonrecurrent and recurrent groups ( Table  1) . The 1-, 3-, and 5-year DFS and OS rates of the 242 patients were 88.8%, 82.8%, and 79.5%; and 89.6%, 76.4%, and 70.7%, respectively (Fig. 1) . Of the 242 patients, 67 (27.7%) died during the follow-up period. The causes of death were HCC recurrence (n 5 31; 46.3%), sepsis (n 5 12; 17.9%), biliary complications (n 5 5; 7.5%), vascular complications (n 5 4; 6.0%), rejection (n 5 3; 4.5%), and other.
Patient demographics and tumor characteristics were compared between the MVI and PVTT groups The AFP (P < 0.001) and PIVKA-II (P 5 0.02) levels differed significantly. The maximal (P 5 0.001) and total (P < 0.001) tumor diameters differed from those of the control group, but not between the MVI and PVTT groups (P 5 1.00). The E-S grade was also significantly higher in the MVI and PVTT groups (P 5 0.01). The extent of recurrence differed NOTE: Data are expressed as n (%) or as mean 6 standard deviation. PVTT was diagnosed when intrathrombus vascularity was evident in the arterial phases of imaging studies (CT or MRI), and/or when the pathologist confirmed the malignancy of a thrombus.
FIG. 2. Comparison of the (A) DFS and (B)
OS rates in patients with HCC by MVI status and PVTT status.
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significantly among the 3 groups (P < 0.001), but the site of recurrence did not (P 5 0.37). The recurrence interval was shortest in the PVTT group (P 5 0.02; Table 2 ). The DFS and OS rates were analyzed by MVI and PVTT status. The 1-, 3-, and 5-year DFS rates in the MVI group were 78.2%, 72.6%, and 64.5% respectively; the rates in the PVTT group were 59.5%, 52.9%, and 52.9%, respectively. DFS was poorer in the PVTT group than in the MVI group (P < 0.001). OS rates were also worse in the PVTT group than in the MVI group (78.9%, 69.7%, 63.3% versus 82.2%, 50.2%, 42.5%; P < 0.001; Fig. 2 ).
Next, we analyzed patient demographics and tumor characteristics by the level at which the PVTT were located. Neither the maximal tumor diameter (P 5 0.24) nor the tumor number (P 5 0.77) differed between groups. The total diameter was somewhat larger in the lobar PVTT group, but statistical significance was not attained (P 5 0.08). The groups did not differ in terms of E-S grade. The recurrence rate was significantly higher in the lobar PVTT group (P 5 0.01), but neither the site of recurrence (P 5 0.63) nor the recurrence interval (P 5 0.93) differed (Table 3) . We compared the DFS and OS rates by MVI, segmental PVTT, and lobar (Fig. 3) . We performed subgroup analysis of patients with segmental PVTT by recurrence status. The preoperative AFP level was somewhat higher in the recurrent group, but statistical significance was not attained (P 5 0.27). However, patients with AFP levels > 100 ng/mL were at greater risk of recurrence (33.3% versus 88.9%, P 5 0.01). No difference in the maximal (P 5 0.96) or total (P 5 0.70) tumor diameter or tumor number (P 5 0.27) was detected between groups. The E-S grade also did not differ (P 5 0.16; Table 4 ). We next analyzed the DFS and OS rates based on an AFP level of 100 ng/mL. Significant differences were evident in the DFS (P 5 0.008) and OS (P 5 0.044) rates (Fig. 4) . NOTE: Data are expressed as n (%) or as mean 6 standard deviation. Segmental PVTT: PVTT at or below the second-order branch of the PV. Lobar PVTT: PVTT at the first-order branch of the PV.
FIG. 4. Comparison of the (A) DFS and (B)
OS rates in subgroup analysis of patients with segmental PVTT based on AFP level of 100 ng/mL.
Discussion
In regions with few deceased donors, LDLT is an alternative; the outcomes of LDLT and DDLT do not differ. LDLT is associated with some absolute contraindications, but donor safety and the expected benefits to the recipient often determine whether transplantation is performed. Generally, expanded criteria are acceptable. This is also true for patients with PVTT, which is a well-known complication of HCC. Approximately 35% of patients with HCC develop PVTT (7, 8) associated with advanced disease; such patients are generally excluded from LT when the Milan criteria are employed. These criteria have been widely accepted since 1996. However, in recent years, many transplant communities have sought to expand these conventional selection criteria to include patients with HCC for whom LT can prolong survival. However, there are few reports of post-LT results according to the PVTT level. (9, 10) So, we sought to define the branch levels in which PVTT presence was acceptable in LT.
MVI is an important prognostic factor for HCC recurrence, especially after LT. (11) MVI is defined as a tumor within a vascular space lined by endothelium, and it is identifiable only microscopically. (12) However, the mechanism of MVI remains largely controversial because MVI is not known before surgery even in tumors within Milan criteria and no current imaging modalities or laboratory tests can correctly depict it. Therefore, LT has been performed regardless of MVI in such patients, who usually exhibit poor tumor biology (elevated AFP and PIVKA-II levels and high E-S grades) and adverse morphology (a large tumor or several tumors); both factors negatively impact recurrence and survival. In our study, MVI patients differed in tumor morphology and tumor biology from patients without MVI, and MVI patients showed poor results in recurrence, DFS, and OS.
HCC exhibits a high propensity to invade the portal venous system, creating a PVTT, (13) which is the most common form of macrovascular invasion. Likewise, the differentiation of benign from malignant PV thrombi is difficult in the absence of histological examination. (14) Careful observation is needed for accurate diagnosis. Furthermore, a PVTT below the secondorder branch is difficult to identify accurately on preoperative images, and there were few reports on the posttransplant prognoses of patients with PVTT below the second-order branch. Lee et al. reported that the level of PVTT affects tumor recurrence after LT. (9) However, the result of this study is based on a small number of patients (n 5 11). Clinically, a PVTT is associated with a large tumor size, an increased tumor number, a higher tumor grade, a worse Child-Pugh class, and a higher serum AFP level. (15) In the present study, PVTT was associated with significantly poorer tumor biology (elevated serum AFP and PIVKA-II levels), but no significant deterioration in morphology (tumor size or number) compared with those of patients in the MVI group. As the recurrence rate increases and the recurrence interval decreases, the DFS and OS rates begin to vary significantly.
Generally, as the tumor progresses, the PVTT proceeds from a relatively smaller branch of the PV to a relatively larger branch (the subsegmental or segmental PV), and it may later involve the first branch of the PV (the lobar PV) and indeed the main PV. When a PVTT is present in a relatively large PV, it may be detected radiologically. However, segmental PVTT is limited in preoperative diagnosis. Rossi et al. (16) detected only 65% of PVTTs in the segmental (second-order branch) PV by imaging study. The preoperative diagnosis of PVTT below the segmental branch showed 59.3% in our data. Therefore, there is a limit to the preoperative diagnosis of segmental PVTT at present. However, if preoperative diagnostic techniques are developed and the preoperative diagnosis rate is increased, it will be more useful for clinical applications.
We further subgrouped the data to compare patients with segmental and lobar PVTT. Lobar PVTT had larger average maximal and total diameters than segmental PVTT, but statistical significance was not attained because the numbers of cases were small. The recurrence interval did not differ between groups, but the recurrence, DFS, and OS rates did. In particular, the 5-year OS rate in the lobar PVTT group was 14.3%, which may be a contraindication for LT. However, in the segmental PVTT group, the 5-year DFS and OS rates were 63.9% and 50.3%, respectively, and did not differ significantly from those of the MVI group. In general, as the expected 5-year survival rate of patients with HCC is known to be at least 50%, segmental PVTT does not preclude transplantation when the interests of the donor and recipient are met.
The AFP and PIVKA-II levels associated with tumor activity have been reported to affect tumor recurrence after LT. An increasing number of studies has shown that the preoperative AFP level and the vascular invasion are predictors of tumor recurrence or metastasis. (17) (18) (19) Our study also showed the same results. Thus, the preoperative AFP level is important. We found that the preoperative AFP level was higher in the recurrent, MVI, and PVTT groups. It also seemed to be higher in relapsing patients with segmental PVTT, although the group was too small to afford the necessary statistical power. However, the proportion of patients with AFP levels > 100 ng/mL was higher in the recurrent group. Upon survival analysis based on AFP levels of 100 ng/mL and <100 ng/mL, the 5-year DFS and OS rates were favorable (90.9% and 71.3%, respectively). However, when the AFP level is >100 ng/mL and PVTT is suspected, LT should be performed with caution because the tumor lies close to the PV branch. However, since there are not enough cases to conclude, further studies are essential.
The limitations of this study include the retrospective nature of the work and the imbalance in group patient populations. Further studies with more cases are needed. In addition, preoperative diagnosis of PVTT is difficult. Tumor thrombi in small branches below the second-order branch require especially meticulous exploration.
In conclusion, LT has become one of the most effective modalities by which to treat HCC. Lobar PVTT remains a contraindication for LT. However, the presence of segmental PVTT may be acceptable. To achieve better results, we recommend that the AFP level be considered when selecting patients with segmental PVTT. Future longterm, large-scale analyses of clinical data are required to develop more appropriate criteria for selection of patients with HCC and segmental PVTT for inclusion on LT waiting lists.
